- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Tearing Down Silos to Usher Innovative Medicines to Patients Faster
Fran Pollaro talks with Cathi Ahearn, senior vice president, worldwide commercial portfolio strategy, Bristol Myers Squibb about impediments and solutions to break down silos in order to get medications in the hands of patients faster.
Cathi Ahearn is a seasoned biotechnology leaders with formative stints at Genentech, Roche, and now at Bristol Myers Squibb, as SVP of worldwide commercial portfolio strategy. Cathi is focused on one goal: shortening the path between creating medical innovation and getting that innovation to patients. Cathi chats with senior editor at Pharmaceutical Executive about her experiences in the past 20+ years and most importantly, the power of cross-functional collaboration, bringing different teams together and tearing down silos that limit the impact new innovations can have for patients.
About the speaker
Cathi joined Bristol Myers Squibb in December 2021 to lead Worldwide Commercial Portfolio Strategy, including responsibility for commercial development of pipeline assets, global marketing of in-line brands, and optimized management of the established brands franchise. She is a seasoned biotechnology leader who spent 22 years in roles of increasing responsibility and scope at Roche/Genentech, primarily in oncology. Her strategic, results-driven mindset led to demonstrated successes building and developing successful teams. Most recently, she led the GI & GU and Cancer Immunotherapy franchises within Roche’s worldwide commercial organization. Cathi led the cross-functional lifecycle & franchise teams for Tecentriq, Roche’s anti-PDL1 program, from the time of its entry into clinic through its global licensing and commercialization. Cathi held a broad range of US sales, marketing, and strategic roles on the Avastin program, and in the cardiovascular and asthma/allergy disease areas.
Cathi holds a Bachelor of Arts in Psychology from UCLA and a Master of Business Administration from the Fuqua School of Business at Duke University.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
